Mesenchymal stem cell therapy: A promising cell‐based therapy for treatment of myocardial infarction

Shafei, Ayman El Sayed; Ali, Mahmoud; Ghanem, Hazem G.; Shehata, Ahmed I.; Abdel-Gawad, A. A.; Handal, Hossam R.; Talaat, Kareem A.; Ashaal, Ahmed E.; El‐Shal, Amal S.

doi:10.1002/jgm.2995

Cited by 132 publications

(95 citation statements)

References 137 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Involvement of EVs has been implicated in regenerative effects of MSCs in a wide variety of tissues including skin, muscle, neural tissues, lung, vascular tissue, bone, and cartilage [21,[23][24][25][26][27][28][29]. MicroRNA (miRNA) has been frequently cited as an important mediator of the biological effects of MSCsecreted EVs [1,23,24,30,31].…”

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stem Cells Reduce Corneal Fibrosis and Inflammation via Extracellular Vesicle-Mediated Delivery of miRNA

Shojaati

Khandaker

Funderburgh

et al. 2019

Stem Cells Translational Medicine

133

114

View full text Add to dashboard Cite

Mesenchymal stem cells from corneal stromal stem cells (CSSC) prevent fibrotic scarring and stimulate regeneration of transparent stromal tissue after corneal wounding in mice. These effects rely on the ability of CSSC to block neutrophil infiltration into the damaged cornea. The current study investigated the hypothesis that tissue regeneration by CSSC is mediated by secreted extracellular vesicles (EVs). CSSC produced EVs 130–150 nm in diameter with surface proteins that include CD63, CD81, and CD9. EVs from CSSC reduced visual scarring in murine corneal wounds as effectively as did live cells, but EVs from human embryonic kidney (HEK)293T cells had no regenerative properties. CSSC EV treatment of wounds decreased expression of fibrotic genes Col3a1 and Acta2, blocked neutrophil infiltration, and restored normal tissue morphology. CSSC EVs labeled with carboxyfluorescein succinimidyl ester dye, rapidly fused with corneal epithelial and stromal cells in culture, transferring microRNA (miRNA) to the target cells. Knockdown of mRNA for Alix, a component of the endosomal sorting complex required for transport, using siRNA, resulted in an 85% reduction of miRNA in the secreted EVs. The EVs with reduced miRNA were ineffective at blocking corneal scarring. Furthermore, CSSC with reduced Alix expression also lost their regenerative function, suggesting EVs as an obligate component in the delivery of miRNA. The results of these studies support an essential role for extracellular vesicles in the process by which CSSC cells block scarring and initiate regeneration of transparent corneal tissue after wounding. EVs appear to serve as a delivery vehicle for miRNA, which affects the regenerative action. Stem Cells Translational Medicine 2019;8:1192–1201

show abstract

Section: Introductionmentioning

confidence: 99%

Mesenchymal Stem Cells Reduce Corneal Fibrosis and Inflammation via Extracellular Vesicle-Mediated Delivery of miRNA

Shojaati

Khandaker

Funderburgh

et al. 2019

Stem Cells Translational Medicine

133

114

View full text Add to dashboard Cite

show abstract

“…Many recent studies have suggested that the secretion of GFs and other bioactive molecules may be one of the primary mechanisms whereby MSCs mediate their therapeutic efficacy. These secreted compounds can inhibit a range of processes such as apoptotic cell death and fibrosis, 11 in addition to being able to drive angiogenesis, 12,13 and to regulate the immune response. 14,15 Without any exogenous manipulation, MSCs achieve limited therapeutic efficacy due to their poor survival and limited GF secretion upon transplantation.…”

Section: The Relationship Between Msc Biology and Gf Secretionmentioning

confidence: 99%

“…To that end, studies have explored the use of MSCs modified to express certain exogenous genes that can enhance their ability to promote angiogenesis and target tissue homing. 13,20 These genetically engineered MSCs can thereby both improve MSC engraftment and functionality, while also allowing for the targeted delivery of therapeutic gene products that can enhance local tissue healing. 21 Indeed, MSCs can secret a broad profile of active molecules including hematopoietic growth factors, angiogenic growth factors, trophic molecules, immunomodulatory cytokines, and chemokines.…”

Section: The Relationship Between Msc Biology and Gf Secretionmentioning

confidence: 99%

“…The therapeutic value of MSCs stems largely from their ability to mediate angiogenesis and tissue regeneration, 75 secreting GFs and exosomes to achieve therapeutic efficacy and homing to target tissue sites. 9,16,17 A number of preclinical studies to date have sought to use genetically-modified MSCs that secrete GFs in order to treat a wide range of conditions associated with tissue injuries.…”

Section: Preclinical Use Of Gf-modified Mscs In Tissue Regenerationmentioning

confidence: 99%

See 1 more Smart Citation

<p>Growth Factor Gene-Modified Mesenchymal Stem Cells in Tissue Regeneration</p>

Nie¹,

Zhang²,

Wang³

2020

DDDT

View full text Add to dashboard Cite

There have been marked changes in the field of stem cell therapeutics in recent years, with many clinical trials having been conducted to date in an effort to treat myriad diseases. Mesenchymal stem cells (MSCs) are the cell type most frequently utilized in stem cell therapeutic and tissue regenerative strategies, and have been used with excellent safety to date. Unfortunately, these MSCs have limited ability to engraft and survive, reducing their clinical utility. MSCs are able to secrete growth factors that can support the regeneration of tissues, and engineering MSCs to express such growth factors can improve their survival, proliferation, differentiation, and tissue reconstructing abilities. As such, it is likely that such genetically modified MSCs may represent the next stage of regenerative therapy. Indeed, increasing volumes of preclinical research suggests that such modified MSCs expressing growth factors can effectively treat many forms of tissue damage. In the present review, we survey recent approaches to producing and utilizing growth factor gene-modified MSCs in the context of tissue repair and discuss its prospects for clinical application.

show abstract

“…Further studies have shown that injection of MSCs to infarcted heart decreases infiltration of inflammatory cells (Shafei et al, 2017).…”

Section: Role Of Different Types Of Stem Cells In Post Myocardial Imentioning

confidence: 99%

Stem cell therapy: A novel approach for myocardial infarction

Parizadeh

Jafarzadeh‐Esfehani

Ghandehari

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

Myocardial infarction (MI) is a major cause of morbidity and mortality worldwide. Until recently, it was thought that myocardium was not able to repair itself, but studies have now shown that resident cardiac stem cells have regenerative capacity, and stem cell therapy may be a novel approach for cardiac muscle repair and regeneration. Stem cell‐derived paracrine factors have been shown to regulate ventricular remodeling, inflammation, apoptosis, cardiomyocytes regeneration, and neovascularization in regions of infarcted cardiac tissue. In this review, we summarize the evidence from cellular, animal, and clinical studies supporting the potential clinical significance of stem cell therapy as a novel therapeutic approach for the treatment of MI.

show abstract

Mesenchymal stem cell therapy: A promising cell‐based therapy for treatment of myocardial infarction

Cited by 132 publications

References 137 publications

Mesenchymal Stem Cells Reduce Corneal Fibrosis and Inflammation via Extracellular Vesicle-Mediated Delivery of miRNA

Mesenchymal Stem Cells Reduce Corneal Fibrosis and Inflammation via Extracellular Vesicle-Mediated Delivery of miRNA

<p>Growth Factor Gene-Modified Mesenchymal Stem Cells in Tissue Regeneration</p>

Stem cell therapy: A novel approach for myocardial infarction

Contact Info

Product

Resources

About